Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2011

View Archived Issues

SK Biopharmaceuticals divulges preclinical data on SKL-A4R

Novartis discloses final results from EXIST-2 trial

Data presented from phase I trial of OPB-31121 in advanced solid malignancies

FDA accepts Amarin's NDA for AMR-101

Supernus commences U.S. phase IIb study of SPN-810

Multi-biomarker panel may monitor clinical disease activity in subjects with RA

Ongoing trial investigates effects of bevacizumab in neoplastic meningitis

Scientists at Karus Therapeutics prepare new PI3K inhibitors

French researchers patent novel kinase inhibitors

Astex Pharmaceuticals presents novel anticancer compounds

Phase IIb trial of RVX-208 in high-risk cardiovascular disease completes enrollment

Proximagen and Altacor enter agreement for serotonin 5-HT2C program

Cytokinetics begins third phase II trial of CK-2017357 in ALS

University of Edinburgh discloses new 11-beta-HSD1 inhibitors

FDA accepts Lodotra NDA for review

Compugen and DiscoveRx collaborate on novel peptide ligands

Omeros submits pediatric investigation plan to EMA for OMS-302

Japanese team synthesizes novel MMP-9 inhibitors

BMS obtains approval for additional indication for Paraplatin in Japan

Infinity and Mundipharma extend strategic alliance for PI3K inhibitors

FDA accepts Eliquis NDA for review

OncoVista secures CRO for phase Ib study of cordycepin

BioMarin begins study of GALNS in young patients with MPS IVA

Provectus gives update on program for PV-10 in metastatic melanoma

Soliris approved in Europe for treatment atypical hemolytic uremic syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.